Why the study?
Does switching to an angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) reduce the risk of new-onset atrial fibrillation compared to continuing traditional RAS blockade in patients with HFrEF without prior atrial fibrillation?
Does switching to an angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) reduce the risk of new-onset atrial fibrillation compared to continuing traditional RAS blockade in patients with HFrEF without prior atrial fibrillation?
Answers are grounded in this paper and cite their sources.
This editorial highlights that while nationwide observational data suggest switching to sacubitril/valsartan is associated with an 11% reduction in new-onset atrial fibrillation in HFrEF, unmeasured confounding and null randomized trial data make this finding hypothesis-generating until confirmed by a dedicated RCT.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Volpe et al. (2026) conducted an editorial in Heart failure with reduced ejection fraction (HFrEF) without prior atrial fibrillation (n=18,060). Switching to angiotensin receptor-neprilysin inhibitor (ARNI; sacubitril/valsartan) vs. Continuing traditional renin-angiotensin system (RAS) blockade (ACE inhibitors or ARBs) was evaluated on New-onset atrial fibrillation at 1 year (11% reduction, p=0.021).
Synapse has enriched 10 related papers. Consider them for comparative context: